GFM
PTGX icon

GF Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

GF Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Sell
1,353
-51
-4% -$5.33K ﹤0.01% 291
2026
Q1 		$148K Buy
1,404
+177
+14% +$15.7K ﹤0.01% 306
2025
Q4 		$107K Sell
1,227
-111
-8% -$9.09K ﹤0.01% 339
2025
Q3 		$88.9K Sell
1,338
-188
-12% -$10.7K ﹤0.01% 344
2025
Q2 		$84.3K Hold
1,526
– – ﹤0.01% 381
2025
Q1 		$73.8K Buy
1,526
+275
+22% +$11.5K ﹤0.01% 386
2024
Q4 		$48.3K Buy
+1,251
New +$54.5K ﹤0.01% 392

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GF Fund Management's PTGX Position: Q2 2026 in Review

GF Fund Management reduced its Protagonist Therapeutics (PTGX) stake by 3.6% in Q2 2026, selling an estimated $5.33K and leaving 1,353 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #291.

GF Fund Management first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • GF Fund Management held 1,353 shares of Protagonist Therapeutics worth $166K as of Q2 2026.
  • GF Fund Management sold 51 Protagonist Therapeutics shares in Q2 2026, an estimated $5.33K.
  • Protagonist Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #291 holding.
  • GF Fund Management first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.